Press Releases

Twitter iconYouTube iconFacebook iconSoundCloudiTunes badge

Call us: +44 (0)20 7679 9041


The UCL Media Relations team is the university’s central press office.


We connect journalists to expert academics and promote UCL research and teaching throughout the global media.


More contact information



Professor Quentin Pankhurst to head the new Davy-Faraday Research Laboratory at the Royal Institution

Publication date: Apr 29, 2008 2:24:14 PM

Following a two and a half year closure for an extensive £22 million renovation, the Royal Institution of Great Britain (RI) announced that Professor Quentin Pankhurst, Deputy Director of the London Centre for Nanotechnology, University College London, is to take up the post of Director at the Davy-Faraday Research Laboratory (DFRL), previously held by Professor Richard Catlow. Professor Pankhurst will focus on Healthcare Biomagnetics – the application of magnetic materials to healthcare.

A defining tenet of the RI is that it should be actively engaged in innovative research undertaken by its own resident scientists. The DFRL has a long and distinguished 200 year history, including the award of 14 Nobel Prizes, the discovery of 10 elements of the periodic table and the invention of the electric generator.

In his new position, from 1st May 2008, Professor Pankhurst will undertake an ambitious collaborative research programme to build a new DFRL team of up to 15 resident scientists, engineers, medics and technologists to tackle major challenges in the field of Healthcare Biomagnetics. In addition, a joint UCL-RI programme will enable at least another 35 scientists to make direct use of the new DFRL facilities.

The proposed Healthcare Biomagnetics programme at the DFRL will be jointly funded by a £2.35 million commitment from the RI and an investment of £1.36 million from UCL from April 2008 until March 2013.

Professor Pankhurst and his team will be working to make a difference for patients all over the world by perfecting new ways to sense, move and heat magnets which can be safely and conveniently introduced into the human body in the form of a magnetic ‘ink’. Examples of on-going projects include the development of:

  • a hand-held scanner that helps cancer surgeons determine the progression of cancer in a patient;
  • a method for targeting and activating magnetic particles to cause selective localised heating and destruction of cancer cells

Professor Quentin Pankhurst said: “My goal for the new DFRL is to create a new paradigm for cross-disciplinary applied research that has technology transfer firmly in its sights. The Healthcare Biomagnetics area is one of tremendous promise and it would certainly be recognised by the laboratory’s forbears: Sir Humphrey Davy was an apprentice surgeon before making his name at the RI for his work on anaesthetics, and Michael Faraday is undoubtedly the father of modern electricity and magnetism.”

Baroness Susan Greenfield, Director of the RI, said: “We are delighted to welcome Professor Pankhurst and his team to the new Davy-Faraday Research Laboratory as part of the refurbished Royal Institution. This is the latest chapter in the long and illustrious history of groundbreaking research here in Albemarle St and I’m confident the DFRL will continue to be a cornerstone of scientific discovery.”

Professor Malcolm Grant, UCL President and Provost, said: "This is an exciting venture for both UCL and the Royal Institution, demonstrating our ongoing commitment to groundbreaking scientific investigation."

After a £22 million, two-year upgrade; the new Royal Institution will be launched in an official ceremony with Her Majesty the Queen at the end of May, and will welcome all types of visitors through its iconic doors once again on 1st July.

For more information visit www.rigb.org

-ENDS-

For further information contact, please contact Dave Weston in the UCL Press Office on +44 (0) 20 7679 7678 or d.weston@ucl.ac.uk

Notes to editors

Professor Quentin Pankhurst

Professor Pankhurst has more than 20 years’ academic experience in the study of fine particle magnetism and has published more than 150 papers in peer-refereed international journals. He is currently Deputy Director of the London Centre for Nanotechnology and a Professor of Physics at University College London. Born in New Zealand, he came to the UK in 1983 to study solid state physics at the University of Liverpool, where he was until joining UCL in 1994. Prof Pankhurst now runs research programmes in bio- and nanomagnetism dedicated to making practical advances in the use of magnetic nanoparticles in healthcare. He is the co-founder of Endomagnetics Ltd, which is currently running clinical trials of the SentiMag, an intra-operative device for cancer surgery.

The Royal Institution of Great Britain (Ri)

Since its establishment over 200 years ago, 14 scientists closely connected with the Ri have won the Nobel Prize. Ten chemical elements of the Periodic Table have been isolated by those who have worked in the building.

During these two centuries famous figures such as Humphry Davy, Michael Faraday, James Dewar and William and Lawrence Bragg have researched, lectured and lived in the Ri. Included among their innovative and groundbreaking discoveries made at the Ri, and which still impact on our daily lives, are the electric generator, the miners’ safety lamp and the atomic structure of crystals.

The Ri has always provided open public debate and education about science and scientific issues for people of all ages through its year-round, high-calibre events that break down the barriers between science and society.

The Public and Young Person’s Events Programmes of the Ri deliver independent science-based discussion on an issue where community interest lies. This has included such varied topics as climate change, cutting edge discovery in combating serious illness such as Leukaemia and Alzheimer’s and the ‘The Life Cycle of a Diamond’.

About University College London

Founded in 1826, UCL was the first English university established after Oxford and Cambridge, the first to admit students regardless of race, class, religion or gender, and the first to provide systematic teaching of law, architecture and medicine. In the government's most recent Research Assessment Exercise, 59 UCL departments achieved top ratings of 5* and 5, indicating research quality of international excellence.

UCL is in the top ten world universities in the 2007 THES-QS World University Rankings, and the fourth-ranked UK university in the 2007 league table of the top 500 world universities produced by the Shanghai Jiao Tong University. UCL alumni include Marie Stopes, Jonathan Dimbleby, Lord Woolf, Alexander Graham Bell, and members of the band Coldplay. Website: www.ucl.ac.uk

London Centre for Nanotechnology

The London Centre for Nanotechnology is an interdisciplinary joint enterprise between University College London and Imperial College London. In bringing together world-class infrastructure and leading nanotechnology research activities, the Centre aims to attain the critical mass to compete with the best facilities abroad. Research programmes are aligned to three key areas, namely Planet Care, Healthcare and Information Technology and bridge together biomedical, physical and engineering sciences. Website: www.london-nano.com

Healthcare Biomagnetics

Healthcare Biomagnetics is an extremely promising field at the interface of physical and life sciences and engineering which has tremendous potential in many aspects of translational medicine. These include the development of new understandings and approaches to treating cancer, cardiovascular disease and regenerative medicine, as in the following:

· the designing and building of a biomagnetometer for use by cancer surgeons to locate key cells for biopsy;

· the use of labelled stem cells for directed treatment of cardiovascular disease coupled with on-line MRI tracking of the cells;

· the bioengineering of antibodies for specialised treatment of colorectal and other cancers; and

· the synthesis and characterisation of multi-functional nanoparticles for in vitro imaging and sensing.

Together these embody a new platform technology in the biomedical application of magnetic nanoparticles. It is an extremely promising area of applied research, with well-recognised prospects of delivery over the next decade.